close :

:

Forgotten your password?
 
Clinical Trials
Printable Version   Email to a friend

Best Practice Database: Complimentary Excerpt of Scientific Publications Strategy Study

CHAPEL HILL, N.C., March 26, 2008 /PRNewswire/ -- An article this week in The Wall Street Journal said Merck & Co. and Schering-Plough Corp. kept a study of their blockbuster drug Vytorin under wraps for more than a year because of data concerns. The article went on to say the study - which found Vytorin was no better than a generic - has renewed concern over the practice of selective publication.

As the debate continues over how pharma companies manage the scientific publications process, organizations are adjusting their publication operations, according to research from benchmarking leader Best Practices, LLC. For instance, some companies have shifted their global publications functions out of commercial and into medical operations, according to the study.

The study, Scientific Publications Strategy: Managing Reputation, Clinical Trial Results, is available in the Best Practice Database, an online resource that contains more than $35 million in proprietary research conducted on behalf of executives from Fortune 500 companies.

A complimentary excerpt of the publications study is available at http://www.best-in-class.com/dr292.htm .

The study illustrates how pharmaceutical companies are following a publishing strategy that presents all study findings while still driving brand strength through commercially relevant publications. Publishing leaders from pharma and biotech companies can use this research to evaluate the resources and strategies of their publication operations.

    Key topic areas covered in the study include:


     -- Global Publications Structure and Functional Home (Medical vs.

        Marketing)

     -- Key Contributors and Stakeholders in Strategy Development and Plan

        Delivery

     -- Effective Publications Vehicles, Content and Audiences

     -- Using Alternative Media

     -- Planning for Neutral/Negative Results

     -- Changes in Resources and Outsourcing

     -- Measuring Performance

     -- Strategic Next Steps

For more information, contact Jeff Zimmer, Senior Research Analyst, at 919-767-9180 or at . To access the full report or download a complimentary copy of the report summary, go to http://www3.best-in-class.com/dr292.htm . jzimmer@best-in-class.com

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class organizations. For more information, call 919-403-0251 or visit http://www.best-in-class.com .

CONTACT: Kimberly Hardin of Best Practices, LLC, +1-919-767-9221, khardin@best-in-class.com

Web site: http://www.best-in-class.com/http://www3.best-in-class.com/dr292.htm/

Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Clinical Trial Results...

Clinical Trial Results Archive

2008: Jan | Feb | Mar | Apr | May
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec

More News Resources


Join Drugs.com
Click here to see what benefits you can get by joining our FREE membership programme.
Drugs.com is the most popular, comprehensive, and up-to-date source of drug information online. Providing advice on more than 24,000 prescription drugs and over-the-counter medicines for consumers and professionals .
Advertisement
In The Pipeline